Enhabit (NYSE:EHAB – Get Free Report) issued its earnings results on Wednesday. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05, FiscalAI reports. The firm had revenue of $263.60 million for the quarter, compared to the consensus estimate of $267.08 million. Enhabit had a positive return on equity of 2.72% and a negative net margin of 12.84%. Enhabit updated its FY 2025 guidance to 0.500-0.560 EPS.
Enhabit Stock Performance
Shares of NYSE:EHAB traded down $0.30 during trading hours on Thursday, hitting $7.91. The stock had a trading volume of 237,345 shares, compared to its average volume of 430,599. Enhabit has a 1-year low of $6.47 and a 1-year high of $10.90. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.57 and a current ratio of 1.57. The firm has a market capitalization of $400.96 million, a price-to-earnings ratio of -2.96 and a beta of 1.69. The stock’s fifty day simple moving average is $8.09 and its 200 day simple moving average is $8.37.
Insider Transactions at Enhabit
In other Enhabit news, CFO Ryan Solomon purchased 10,000 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $7.64 per share, for a total transaction of $76,400.00. Following the completion of the transaction, the chief financial officer owned 193,468 shares in the company, valued at $1,478,095.52. This represents a 5.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.40% of the company’s stock.
Institutional Investors Weigh In On Enhabit
Analysts Set New Price Targets
Several equities research analysts recently commented on EHAB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enhabit in a report on Wednesday, October 8th. UBS Group lowered their price objective on Enhabit from $10.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enhabit presently has a consensus rating of “Hold” and an average target price of $8.67.
View Our Latest Analysis on EHAB
About Enhabit
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Further Reading
- Five stocks we like better than Enhabit
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Tempus AI: Volatility Equates to Opportunity in AI Leader
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Follow the Money: 3 Stocks With High Institutional Ownership
- Where to Find Earnings Call Transcripts
- Can Gold Mining Stocks Shine as the Metals Rally Falters?
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.
